Nanoparticle-mediated Targeting of the Fusion Gene RUNX1/ETO in t(8;21)-positive Acute Myeloid Leukemia [ATAC-seq]. Nanoparticle-mediated Targeting of the Fusion Gene RUNX1/ETO in t(8;21)-positive Acute Myeloid Leukemia [ATAC-seq]

To investigate the therapeutic potential of targeting RUNX1/ETO with lipid nanoparticles encapsulating chemically modefied siRNA. Chromatin Accessibility (ATAC-seq) was performing on cells lines after lipid nanoparticles in vitro. Overall design: Comparative chromatin accessibilty from in vitro treatment with active siRNA against RUNX1/ETO (LNP/siRE-mod) and control siRNA (LNP/siMM-mod).

本研究旨在探究利用包裹化学修饰小干扰RNA（small interfering RNA, siRNA）的脂质纳米颗粒（lipid nanoparticles, LNP）靶向RUNX1/ETO的治疗潜力。本研究通过体外实验，对经脂质纳米颗粒处理的细胞系开展染色质开放性ATAC-seq（转座酶可及性测序）检测。实验设计：对比两组经体外处理的细胞的染色质开放性，一组采用靶向RUNX1/ETO的活性siRNA包裹脂质纳米颗粒（LNP/siRE-mod），另一组采用对照siRNA包裹脂质纳米颗粒（LNP/siMM-mod）。